Arctic Bioscience AS is a public limited company, incorporated in accordance with Norwegian law. Arctic Bioscience was listed on Euronext Growth, Oslo on 24 February 2021, under the ticker ABS-ME.

Arctic Bioscience is a biotech company developing unique pharmaceutical and nutraceutical products based on bioactive marine compounds. The company is developing a novel, cost-efficient oral treatment for mild-to-moderate psoriasis – a large global market with significant unmet medical need. Nutraceutical products are sold globally both B2C and B2B under the brand name ROMEGA™. Our story and growth potential is not only reflected in our current business figures but also the latest developments on the stock market.